Monday, March 24, 2014

Inovio (INO) New Interview with Dr. Kim about Inovio's research and treatment for cancer.

Money Matters 14-11

Hosts:   David Ebner of Merrill Lynch & Charlie Shields of Wells Fargo Advisors, LLC
Guests:   J. Joseph Kim, Ph. D., CEO, of Inovio Pharmaceuticals
Description:   Dave & Charlie talk about investing and then interview Dr. Kim about Inovio's research and treatment for cancer.

Click link here to watch now-Watch Interview

Friday, March 21, 2014


17-19 September 2014, Switzerland (INOVIO will co-sponsor this conference)

"This CAVAD 2014 conference brings together 
experts in both fields of mabs and vaccines to address these important issues.
CAVAD 2014 will offer a new international forum to review the current state of research and development of monoclonal antibodies and vaccines for cancer therapy". 

Conference Co-Chairs: 
Niranjan Sardesai (Inovio Inc., Blue Bell, Pennsylvania, USA) 
(other co-chairs listed on conference site)

CAVAD 2014 will include keynote presentations from leading researchers, submitted oral and poster presentations, and special discussion/panel sessions

1-Abstracts for both oral and poster presentation are called for in the principal topics to be covered at CAVAD 2014 which include:

2-Autoimmunity and cancer
Both mabs and vaccines are trying to harness the immune system to recognise and 
attack self/modified antigens on cancer cells. As autoimmunity does this very effectively, 
inducing both T cell and antibody responses, there are good lessons to learn for cancer 

3-Novel targets
As vaccines target intracellular antigens, presented as peptides on MHC molecules, and 
Mabs target cell surface proteins there is obvious synergy in combining these approaches. 
Indeed both cellular and humoral immunity are used in the successful attack on pathogens.

There are still very few approved adjuvants for vaccines that stimulate cellular immunity, 
however new TLR agonists are being developed and the recent approval of a mab targeting 
CTLA-4 and trials with anti-PD.1 mabs suggest novel approaches/combinations.

High avidity CD8 T cells, cytotoxic CD4s and direct killing/growth inhibiting mabs have all 
been shown to mediate potent anti-tumour responses. 

Source-Conference Website

OncoSec (ONCS)June 26-27th, 2014 4th European Post Chicago Melanoma/ Skin Cancer Meeting

Results and Interpretations of ASCO presentations 2014 
(Global confernce on news in melanoma/skin cancer) 

Friday, June 27th 2014
Session- New drugs and trials: An update on immunotherapy and chemotherapy 
9:36- Electroporation (Adil I. Daud)
In addition Punit Dhillion will be in attendance.

Gold sponsors for conference 
Merck, Bristol Myers, GSK, Roche
Further Sponsors
Amgen, Celgene, Delcath, Medac, OncoSec 

Conference Description 
The interactive congress offers a comprehensive overview on all new developments in skin cancer and in particular melanoma therapy and a direct communication with the world´s leading experts in these fields. After being held as a joint meeting with the 8th World Congress on Melanoma and the 10th EADO annual conference 2013 in Hamburg, the congress will return to its origins in Munich in June 2014.
Presently there is an exciting time for the development of new drugs for skin cancer / melanoma treatments. New immunotherapies, selective kinase inhibitors, new vaccines, and other innovative strategies for the intratumoral and systemic use are under development and are approaching the market for melanoma rapidly. Some have already been approved in the recent years. Non-melanoma skin cancer has become an exciting arena for clinical research as well. Several new drugs as hedgehog inhibitors for basal cell carcinomas are currently used in the routine and in innovative trials.
However, it will be the main target for all of us to choose the right patients for the right drugs! The aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma / Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.
International key opinion leaders on melanoma, non-melanoma skin cancer and cutaneous lymphomas will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.   Link-

Inovio (INO) March 2014 Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine

Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine [Epub ahead of print]

  • 1Inovio Pharmaceuticals, Inc., 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422, USA.
  • 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • 3Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Manitoba R2E 3R2, Canada.
  • 4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:


Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses’ ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases.

Note to users: Uncorrected proofs are Articles in Press that have been copy edited and formatted, but have not been finalized yet. They still need to be proof-read and corrected by the author(s) and the text could still change before final publication.
Although uncorrected proofs do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, journal (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an issue of the journal, the Article in Press version will be removed and the final version will appear in the associated published issue of the journal. The date the article was first made available online will be carried over.

Click link for data source-Link

Thursday, March 20, 2014

OncoSec Medical (ONCS) May 21-24, 2014 ASGCT 17th Annual Meeting

Scientific Symposium 213
Thursday May 22, 2014

Richard Heller, PHD

Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase 1 and 2 Trials

Electrotransfer of plasmids encoding cytokines directly to tumors has been shown to generate a local and systemic anti-tumor effect in both preclinical and clinical studies. In the clinical studies, patients with in-transit cutaneous melanoma recevied at least one treatment cycle (days 1,5,8) of intratumor pIL-12 delivered by electrotransfer in up to four lesions per cycle. In both Phase 1 and 2 trials increases in IL-12 levels and enhanced immune activity were observed and the therapy was well tolerated. Intratumor treatment with pIL-12 electrotransfer exhibited a systemic antitumor immune response with activity in both treated and non-treated sites of disease and objective response to treatment. These postive results provide the rationale for an expanded study.    

To visit the conference website follow the link ASGCT

Friday, March 14, 2014

(Inovio) DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques

Abstract 3/13/2014

We tested the concept of combining DNA with protein to improve anti-HIV Env systemic and mucosal humoral immune responses. Rhesus macaques were vaccinated with DNA, DNA&protein co-immunization or DNA prime followed by protein boost, and the magnitude and mucosal dissemination of the antibody responses were monitored in both plasma and mucosal secretions. We achieved induction of robust humoral responses by optimized DNA vaccination delivered by in vivo electroporation. These responses were greatly increased upon administration of a protein boost. Importantly, a co-immunization regimen of DNA&protein injected in the same muscle at the same time induced the highest systemic binding and neutralizing antibodies to homologous or heterologous Env as well as the highest Env-specific IgG in saliva. Inclusion of protein in the vaccine resulted in more immunized animals with Env-specific IgG in rectal fluids. Inclusion of DNA in the vaccine significantly increased the longevity of systemic humoral immune responses, whereas protein immunization, either as the only vaccine component or as boost after DNA prime, was followed by a great decline of humoral immune responses overtime. We conclude that DNA&protein co-delivery in a simple vaccine regimen combines the strength of each vaccine component, resulting in improved magnitude, extended longevity and increased mucosal dissemination of the induced antibodies in immunized rhesus macaques.

About the Authors

Rashmi Jalah, Viraj Kulkarni, Candido Alicea, Barbara K. Felber
Human Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America
Vainav Patel, Margherita Rosati, Jenifer Bear, Antonio Valentin, George N. Pavlakis
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America
Lei Yu, Yongjun Guan
Institute of Human Virology, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
Xiaoying Shen, Georgia D. Tomaras
Duke Human Vaccine Institute and Departments of Surgery and Immunology, Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America
Celia LaBranche, David C. Montefiori
Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
Rajasekhar Prattipati, Abraham Pinter
Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
Julian Bess Jr, Jeffrey D. Lifson
AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
Steven G. Reed
Infectious Disease Research Institute, Seattle, Washington, United States of America
Niranjan Y. Sardesai
Inovio Pharmaceuticals, Inc., Blue Bell, Pennsylvania, United States of America
David J. Venzon
Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

Wednesday, March 12, 2014

Inovio VGX-1027

VGX™-1027 anti-inflammatory drug
VGX™-1027 is an orally administered, small molecule drug for inflammatory diseases. A novel inhibitor of pro-inflammatory responses including TNF-alpha, this drug has demonstrated preclinical efficacy against Crohn’s disease and colitis, rheumatoid arthritis (RA), and Type 1 diabetes (T1D).
VGX-1027 has completed a phase I single-ascending dose, double-blind study in healthy volunteers in which the compound was generally well-tolerated. In keeping with its focus on its synthetic vaccine technology, Inovio plans to out-license this compound.
Inflammatory bowel disease is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. The Centers for Disease Control estimates that as many as 1.4 million persons in the United States suffer from these diseases.
There is no known pharmaceutical or surgical cure for inflammatory bowel diseases. Current treatment includes corticosteroids, antibiotics and new biologics and immune modifiers that mitigate symptoms but do not prevent or cure the disease.
In the U.S. alone, 1.3 million people suffer from RA according to the National Institute of Arthritis and Musculoskeletal Skin Diseases. With significant unmet clinical need and the progressive introduction of higher value and more effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to $27 billion by 2015. Type 1 diabetes (T1D), which can be fatal if untreated, usually strikes children and young adults, although it can strike at any age. In adults, T1D accounts for 5 to 10 percent (0.9 million -1.8 million people) of all diagnosed cases of diabetes in the U.S. alone. Risk factors for T1D may be autoimmune, genetic, or environmental. No known way to prevent type 1 diabetes exists.

By following the link to Inovio's website you can find four abstracts dating from 2007-2008. Information since has been very been limited. Inovio's CEO has been quite over the last few years in regards to clinical work concerning VGX-1027, failing to mentioning the clinical work in any of the company's investor conference presentations. I will note Inovio has a broad pipeline preclinical and clinical and not all data is released via PR update, many studies can be found on pubmed or in medical journals online.
Below I have listed so the most recent updates for VGX-1027
1) March 26th, 2009-VGX Pharmaceuticals Oral Inflammatory Drug Safe In Phase 1 Study
2) July 13th, 2012- Therapeutic Potential of Nitric Oxide -Modified Drugs In Colon Cancer Cells
3) October 24th, 2013 Compounds Having Immunomodulator Activity- Patent (WO2013158794A1)
4) February 14th, 2014 Newest Publication for VGX 1027 

Monday, March 10, 2014

Inovio AACR Conference April 5-9, 2014 San Diego

Presentation of abstract

Tuesday April 8th 2014

Immunoadjuvant ISG15 enhances human papillomavirus

Author- Inovio Pharmaceuticals

Link To Conference Info

The deadline for submission of late-breaking abstracts was Monday, January 27. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline were considered by the AACR Annual Meeting Program Committee for presentation at the AACR Annual Meeting 2014. Only those abstracts that were deemed to be of high scientific priority have been accepted. A special subcommittee of the Program Committee evaluated the merit of late-breaking abstracts. Each late-breaking abstract must have been sponsored by an AACR member.
Authors who submitted abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2014. Each abstract should have contained: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstract submitters were asked to carefully proofread to avoid errors in the published literature and to use American English spelling throughout. For more information regarding American English spelling, please refer to Scientific Style and Format:

The latest Inovio abstracts (INO)

Alarmin IL-33 Acts as an Immunoadjuvant To Enhance Antigen-Specific Tumor Immunity 

March 5th 2014 ahead of print- Inovio Pharmaceuticals

Link to new abstract   

Vaccine Technology IV:An ECI Conference

Feb 25th 2014 - ahead of print Inovio Pharmaceuticals

Link to new abstract  

Thursday, March 6, 2014


Inovio will be included in the special poster session of the conference. Stand by for more details and further updates on INO's presence at the conference as they become available.

The IMV conference series offers a regular update on the developments/issues surrounding ‘immunopotentiators for modern vaccines’ and is a vital aspect of the
growth of this important area of vaccinology.
IMV 2014 will once again offer an international forum to review the current state of research and developments/applications of immunopotentiators/adjuvants for modern
vaccines and associated vaccine programmes/strategies. IMV 2014 will be of interest to researchers involved in determining the mechanisms of adjuvant function and
responses and optimising these responses, manufacturers of biologicals, those involved in the manufacture/licensing of injectable biologicals, and those interested in the
control of infectious and non/infectious diseases

conference link


World Vaccine Congress 2014 
Date- March 24-26, 2014 Location- Washington D.C.

Inovio's presentation's (3/25/2014) Visit the website to see full conference program, in addition Inovio has been nominated for six awards this year by the world vaccine congress voting can also be done by following the link below.

World Vaccine Congress Website